Keryx Biopharmaceuticals Company Profile (NASDAQ:KERX)

About Keryx Biopharmaceuticals

Keryx Biopharmaceuticals logoKeryx Biopharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development of products for the treatment of renal diseases. The Company's product Auryxia (ferric citrate), also known as Riona in Japan and Fexeric in Europe, is an oral, absorbable iron-based compound, which is indicated for the control of serum phosphorus levels in patients with chronic kidney disease (CKD), on dialysis. The Company operates through the products segment. Auryxia can bind to phosphate in the gastrointestinal tract and form non-absorbable complexes to reduce intestinal absorption and aid in the management of hyperphosphatemia in patients with CKD. The adverse events for Auryxia treated patients were gastrointestinal-related, including diarrhea, nausea, constipation, vomiting and cough. The Company focuses on Keryx Patient Plus program to assist with patient accessibility to Auryxia.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: Biotechnology
  • Exchange: NASDAQ
  • Symbol: KERX
  • CUSIP: 49251510
Key Metrics:
  • Previous Close: $4.57
  • 50 Day Moving Average: $5.77
  • 200 Day Moving Average: $5.30
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -8.31
  • P/E Growth: -0.03
  • Market Cap: $483.94M
  • Outstanding Shares: 105,895,000
  • Beta: 4.02
Additional Links:
Companies Related to Keryx Biopharmaceuticals:

Analyst Ratings

Consensus Ratings for Keryx Biopharmaceuticals (NASDAQ:KERX) (?)
Ratings Breakdown: 2 Sell Ratings, 7 Hold Ratings, 3 Buy Ratings
Consensus Rating:Hold (Score: 2.08)
Consensus Price Target: $8.21 (79.63% upside)

Analysts' Ratings History for Keryx Biopharmaceuticals (NASDAQ:KERX)
Show:
DateFirmActionRatingPrice TargetDetails
8/3/2016Cowen and CompanyReiterated RatingNeutralView Rating Details
8/2/2016Raymond James Financial Inc.Boost Price TargetOutperform$7.00 -> $10.00View Rating Details
8/2/2016Ladenburg ThalmannBoost Price TargetBuy$9.00 -> $10.00View Rating Details
8/2/2016Brean CapitalDowngradeBuy -> HoldView Rating Details
8/2/2016FBR & CoDowngradeOutperform -> Market Perform$16.00 -> $7.00View Rating Details
8/2/2016Stifel NicolausDowngradeBuy -> HoldView Rating Details
8/1/2016Maxim GroupDowngradeBuy -> HoldView Rating Details
4/30/2016Morgan StanleyReiterated RatingHoldView Rating Details
3/29/2016BTIG ResearchReiterated RatingSell$2.50View Rating Details
3/9/2016JMP SecuritiesLower Price TargetMarket Outperform$19.00 -> $16.00View Rating Details
2/26/2016JPMorgan Chase & Co.DowngradeOverweight -> NeutralView Rating Details
2/19/2016Citigroup Inc.Lower Price Target$2.50 -> $1.80View Rating Details
8/10/2015Roth CapitalDowngradeBuy -> Neutral$11.00 -> $6.00View Rating Details
8/7/2015MLV & Co.Reiterated RatingBuy$25.00View Rating Details
5/6/2015MizuhoLower Price TargetBuy$25.00 -> $21.00View Rating Details
3/20/2015Oppenheimer Holdings Inc.Lower Price TargetOutperform$22.00 -> $18.00View Rating Details
(Data available from 8/27/2014 forward)

Earnings

Earnings History for Keryx Biopharmaceuticals (NASDAQ:KERX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
10/27/2016        
8/1/2016Q216($0.28)($0.42)$8.60 million$9.30 millionViewListenView Earnings Details
4/28/2016Q116($0.26)($0.39)$6.63 million$6.80 millionViewListenView Earnings Details
2/25/2016Q415($0.25)($0.36)$5.68 million$5.80 millionViewListenView Earnings Details
10/29/2015($0.25)($0.29)$3.91 million$4.21 millionViewListenView Earnings Details
8/5/2015Q215($0.26)($0.26)$2.86 million$2.50 millionViewListenView Earnings Details
5/4/2015Q115($0.30)($0.28)$2.45 million$1.20 millionViewListenView Earnings Details
2/27/2015Q414($0.38)($0.44)$1.39 millionViewListenView Earnings Details
11/6/2014Q314($0.27)($0.38)$0.26 millionViewListenView Earnings Details
8/7/2014Q214($0.25)($0.24)$0.28 millionViewListenView Earnings Details
5/8/2014Q114($0.08)($0.15)$9.91 million$10.00 millionViewListenView Earnings Details
3/12/2014Q413($0.16)($0.21)$2.22 millionViewListenView Earnings Details
11/5/2013Q313($0.11)($0.19)$2.22 millionViewListenView Earnings Details
8/1/2013Q2 2013($0.10)($0.14)ViewListenView Earnings Details
5/7/2013Q1 2013($0.01)($0.03)$5.83 million$7.00 millionViewListenView Earnings Details
3/12/2013Q4 2012($0.08)($0.09)ViewListenView Earnings Details
11/7/2012Q312($0.07)($0.08)ViewN/AView Earnings Details
8/7/2012($0.09)($0.02)ViewN/AView Earnings Details
5/8/2012($0.12)($0.13)ViewN/AView Earnings Details
2/29/2012($0.14)($0.12)ViewN/AView Earnings Details
8/8/2011($0.03)($0.05)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Keryx Biopharmaceuticals (NASDAQ:KERX)
Current Year EPS Consensus Estimate: $-1.2 EPS
Next Year EPS Consensus Estimate: $-0.55 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20161($0.23)($0.23)($0.23)
Q2 20161($0.21)($0.21)($0.21)
Q3 20161($0.23)($0.23)($0.23)
Q4 20161($0.30)($0.30)($0.30)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Keryx Biopharmaceuticals (NASDAQ:KERX)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Keryx Biopharmaceuticals (NASDAQ:KERX)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
8/9/2016Greg MadisonInsiderSell1,622$4.22$6,844.84View SEC Filing  
7/29/2016Scott A. HolmesCFOSell4,935$7.36$36,321.60View SEC Filing  
7/25/2016John F. NeylanInsiderSell1,217$7.43$9,042.31View SEC Filing  
7/15/2016Brian AdamsVPSell1,083$7.01$7,591.83View SEC Filing  
7/5/2016Brian AdamsVPSell660$6.66$4,395.60View SEC Filing  
7/5/2016Greg MadisonCEOSell936$6.66$6,233.76View SEC Filing  
5/9/2016Greg MadisonCEOSell1,873$5.42$10,151.66View SEC Filing  
4/25/2016John F NeylanInsiderSell4,766$5.21$24,830.86View SEC Filing  
4/15/2016Brian AdamsVPSell1,060$5.05$5,353.00View SEC Filing  
4/5/2016Brian AdamsVPSell759$4.50$3,415.50View SEC Filing  
4/5/2016Greg MadisonCEOSell1,078$4.50$4,851.00View SEC Filing  
2/9/2016Greg MadisonCEOSell1,938$3.23$6,259.74View SEC Filing  
1/15/2016Brian AdamsVPSell1,322$3.30$4,362.60View SEC Filing  
1/6/2016Brian AdamsVPSell3,004$5.16$15,500.64View SEC Filing  
1/6/2016Greg MadisonCEOSell4,261$4.83$20,580.63View SEC Filing  
11/4/2015Scott A. HolmesCFOBuy5,000$5.33$26,650.00View SEC Filing  
10/15/2015Brian AdamsVPSell1,011$4.01$4,054.11View SEC Filing  
8/21/2015Scott A HolmesCFOBuy5,000$5.72$28,600.00View SEC Filing  
7/15/2015Brian AdamsVPSell1,086$9.99$10,849.14View SEC Filing  
7/6/2015James F Oliviero IIICFOSell1,943$9.61$18,672.23View SEC Filing  
5/6/2015Michael P TarnokDirectorBuy10,000$9.73$97,300.00View SEC Filing  
4/15/2015Brian AdamsVPSell4,320$12.40$53,568.00View SEC Filing  
4/6/2015James F Oliviero IIICFOSell1,878$11.68$21,935.04View SEC Filing  
4/6/2015Ron BentsurCEOSell1,592$11.68$18,594.56View SEC Filing  
3/6/2015Greg MadisonCOOBuy6,380$12.53$79,941.40View SEC Filing  
2/9/2015Greg MadisonCOOSell6,759$10.95$74,011.05View SEC Filing  
1/5/2015James F Oliviero IIICFOSell5,604$13.79$77,279.16View SEC Filing  
1/5/2015Ron BentsurCEOSell5,574$13.79$76,865.46View SEC Filing  
12/30/2014Ron BentsurCEOSell200,000$14.11$2,822,000.00View SEC Filing  
12/29/2014Ron BentsurCEOSell338,977$13.98$4,738,898.46View SEC Filing  
10/6/2014Ron BentsurCEOSell70,838$15.88$1,124,907.44View SEC Filing  
10/3/2014James F Oliviero IIICFOSell2,694$16.14$43,481.16View SEC Filing  
9/12/2014Ron BentsurCEOSell50,000$14.24$712,000.00View SEC Filing  
9/8/2014James F Oliviero IIICFOSell144,237$15.88$2,290,483.56View SEC Filing  
7/7/2014James F Oliviero IIICFOSell2,054$15.75$32,350.50View SEC Filing  
7/7/2014Ron BentsurCEOSell1,788$15.75$28,161.00View SEC Filing  
4/3/2014James Oliviero IIICFOSell2,087$16.46$34,352.02View SEC Filing  
4/3/2014Ron BentsurCEOSell1,816$16.46$29,891.36View SEC Filing  
3/21/2014James Oliviero IIICFOSell292,483$15.14$4,428,192.62View SEC Filing  
1/3/2014James Oliviero IIICFOSell6,309$12.57$79,304.13View SEC Filing  
1/3/2014Ron BentsurCEOSell5,257$12.57$66,080.49View SEC Filing  
12/30/2013James Oliviero IIICFOSell109,500$12.64$1,384,080.00View SEC Filing  
10/3/2013James Oliviero IIICFOSell1,475$10.25$15,118.75View SEC Filing  
10/3/2013Ron BentsurCEOSell2,505$10.25$25,676.25View SEC Filing  
7/5/2013James F Oliviero IIICFOSell1,438$7.95$11,432.10View SEC Filing  
7/5/2013Ron BentsurCEOSell2,440$7.95$19,398.00View SEC Filing  
5/13/2013James F Oliviero IIICFOSell29,363$8.34$244,887.42View SEC Filing  
10/3/2012James F Oliviero IIICFOSell4,973$2.72$13,526.56View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Keryx Biopharmaceuticals (NASDAQ:KERX)
DateHeadline
News IconSmithfield Donates More Than 25,000 Pounds of Protein to the Food Bank of South Central Michigan to Celebrate Michigan Race Weekend (NASDAQ:KERX)
www.econotimes.com - August 26 at 5:40 PM
finance.yahoo.com logoKERX INVESTOR ALERT: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving Keryx Biopharmaceuticals, Inc. and a Lead Plaintiff Deadline of October 3, 2016 (NASDAQ:KERX)
finance.yahoo.com - August 26 at 5:40 PM
finance.yahoo.com logoIMPORTANT INVESTOR ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Keryx Biopharmaceuticals Inc. and Reminds Investors with Losses In Excess of $100,000 to Contact the Firm (NASDAQ:KERX)
finance.yahoo.com - August 26 at 5:40 PM
finance.yahoo.com logoSHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses In Excess Of $100,000 From Investment In Keryx Pharmaceuticals, Inc. To Contact Brower Piven Before The Lead Plaintiff Deadline In Class Action Lawsuit – KERX (NASDAQ:KERX)
finance.yahoo.com - August 26 at 8:48 AM
finance.yahoo.com logoEQUITY ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Keryx Biopharmaceuticals Inc. and Reminds Investors with Losses in Excess of $100,000 to Contact the Firm (NASDAQ:KERX)
finance.yahoo.com - August 26 at 8:48 AM
finance.yahoo.com logoEQUITY ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Keryx Biopharmaceuticals Inc. and Reminds Investors with Losses In Excess of $100,000 to Contact the Firm (NASDAQ:KERX)
finance.yahoo.com - August 23 at 6:01 PM
finance.yahoo.com logoSHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against Keryx Biopharmaceuticals Inc. (KERX) & Lead Plaintiff Deadline: October 3, 2016 (NASDAQ:KERX)
finance.yahoo.com - August 23 at 10:15 AM
globenewswire.com logoINVESTOR ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Keryx Biopharmaceuticals, Inc. of a Class Action ... - GlobeNewswire (press release) (NASDAQ:KERX)
globenewswire.com - August 22 at 5:53 PM
finance.yahoo.com logoINVESTOR ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Keryx Biopharmaceuticals, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of October 3, 2016 – KERX (NASDAQ:KERX)
finance.yahoo.com - August 22 at 5:53 PM
investornewswire.com logoAnalysts See Sales Of $419.083 For Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) - Investor Newswire (NASDAQ:KERX)
www.investornewswire.com - August 20 at 5:40 PM
finance.yahoo.com logoSHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Keryx Biopharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadline – KERX (NASDAQ:KERX)
finance.yahoo.com - August 20 at 9:58 AM
investornewswire.com logoWill Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) Hit $10 Price Target? - Investor Newswire (NASDAQ:KERX)
www.investornewswire.com - August 19 at 5:49 PM
businesswire.com logoRobbins Arroyo LLP: Keryx Biopharmaceuticals, Inc. (KERX) Misled Shareholders According to a Recently Filed Class ... - Business Wire (press release) (NASDAQ:KERX)
www.businesswire.com - August 19 at 5:49 PM
finance.yahoo.com logoRobbins Arroyo LLP: Keryx Biopharmaceuticals, Inc. (KERX) Misled Shareholders According to a Recently Filed Class Action (NASDAQ:KERX)
finance.yahoo.com - August 19 at 5:48 PM
finance.yahoo.com logoSHAREHOLDER ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Keryx Biopharmaceuticals Inc. and Reminds Investors with Losses In Excess of $100,000 to Contact the Firm (NASDAQ:KERX)
finance.yahoo.com - August 19 at 5:48 PM
capitalcube.com logoETF’s with exposure to Keryx Biopharmaceuticals, Inc. : August 18, 2016 (NASDAQ:KERX)
www.capitalcube.com - August 19 at 8:51 AM
4-traders.com logoKeryx Biopharmaceuticals : Cohen Milstein Sellers & Toll PLLC Announces the Investigation of Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX)
www.4-traders.com - August 18 at 5:51 PM
finance.yahoo.com logoIMPORTANT INVESTOR NOTICE: Lundin Law PC Announces Securities Class Action Lawsuit against Keryx Biopharmaceuticals Inc. and Reminds Investors with Losses in Excess of $100,000 to Contact the Firm (NASDAQ:KERX)
finance.yahoo.com - August 18 at 5:51 PM
finance.yahoo.com logoSHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Keryx Biopharmaceuticals, Inc. of Commencement of a Class Action Lawsuit and a Lead Plaintiff Deadline of October 3, 2016 - KERX (NASDAQ:KERX)
finance.yahoo.com - August 17 at 6:01 PM
finance.yahoo.com logoINVESTOR ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Keryx Biopharmaceuticals Inc. and Reminds Investors with Losses In Excess of $100,000 to Contact the Firm (NASDAQ:KERX)
finance.yahoo.com - August 17 at 6:01 PM
finance.yahoo.com logoSHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against Keryx Biopharmaceuticals Inc. (KERX) & Lead Plaintiff Deadline: October 3, 2016 (NASDAQ:KERX)
finance.yahoo.com - August 16 at 5:57 PM
finance.yahoo.com logoINVESTOR ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Keryx Biopharmaceuticals Inc. and Reminds Investors with Losses in Excess of $100,000 to Contact the Firm (NASDAQ:KERX)
finance.yahoo.com - August 16 at 5:57 PM
finance.yahoo.com logoKERYX BIOPHARMACEUTICALS INC Financials (NASDAQ:KERX)
finance.yahoo.com - August 16 at 5:57 PM
finance.yahoo.com logoSHAREHOLDER NOTICE: Khang & Khang LLP Announces Securities Class Action Lawsuit against Keryx Biopharmaceuticals Inc. and Encourages Investors with Losses In Excess of $100,000 to Contact the Firm (NASDAQ:KERX)
finance.yahoo.com - August 15 at 6:00 PM
investornewswire.com logoWill Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) Surprise Analysts? - Investor Newswire (NASDAQ:KERX)
www.investornewswire.com - August 15 at 5:19 AM
finance.yahoo.com logoSHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Keryx Biopharmaceuticals Inc. (KERX) and Lead Plaintiff Deadline October 3, 2016 (NASDAQ:KERX)
finance.yahoo.com - August 14 at 5:45 PM
4-traders.com logoKERYX BIOPHARMACEUTICALS : Lundin Law PC Announces Securities Class Action Law.. (NASDAQ:KERX)
www.4-traders.com - August 13 at 8:47 AM
finance.yahoo.com logoSHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Keryx Biopharmaceuticals, … (NASDAQ:KERX)
finance.yahoo.com - August 13 at 8:47 AM
finance.yahoo.com logoSHAREHOLDER ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Keryx Biopharmaceuticals Inc. and Reminds Investors with Losses in Excess of $100,000 to Contact the Firm (NASDAQ:KERX)
finance.yahoo.com - August 13 at 8:47 AM
finance.yahoo.com logoINVESTOR ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Keryx Biopharmaceuticals, Inc. of Commencement of a Class Action Lawsuit and a Lead Plaintiff Deadline of October 3, 2016 -- KERX (NASDAQ:KERX)
finance.yahoo.com - August 12 at 5:56 PM
finance.yahoo.com logoSHAREHOLDER ALERT: Rosen Law Firm Reminds Keryx Biopharmaceuticals Inc. Investors of Important Deadline in Class Action - KERX (NASDAQ:KERX)
finance.yahoo.com - August 12 at 5:56 PM
finance.yahoo.com logoINVESTOR NOTICE: Khang & Khang LLP Announces Securities Class Action Lawsuit against Keryx Biopharmaceuticals Inc. and Encourages Investors with Losses In Excess of $100,000 to Contact the Firm (NASDAQ:KERX)
finance.yahoo.com - August 12 at 5:56 PM
News IconINVESTOR ALERT: Brower Piven Encourages Shareholders Who Have Losses In Excess Of $100,000 From Investment In Keryx Pharmaceu... (NASDAQ:KERX)
ih.advfn.com - August 11 at 6:04 PM
finance.yahoo.com logoSHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against Keryx … (NASDAQ:KERX)
finance.yahoo.com - August 11 at 6:04 PM
finance.yahoo.com logoThe Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Keryx Pharmaceuticals, Inc. Investors and Encourages Investors to Contact the Firm (NASDAQ:KERX)
finance.yahoo.com - August 11 at 6:04 PM
finance.yahoo.com logoSHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against Keryx Biopharmaceuticals Inc. (KERX) and Lead Plaintiff Deadline: October 3, 2016 (NASDAQ:KERX)
finance.yahoo.com - August 11 at 6:04 PM
finance.yahoo.com logoDEADLINE ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Keryx Biopharmaceuticals Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm (NASDAQ:KERX)
finance.yahoo.com - August 11 at 6:04 PM
finance.yahoo.com logoINVESTOR ALERT: Brower Piven Encourages Shareholders Who Have Losses In Excess Of $100,000 From Investment In Keryx Pharmaceuticals, Inc. To Contact Brower Piven Before The Lead Plaintiff Deadline In Class Action Lawsuit (NASDAQ:KERX)
finance.yahoo.com - August 11 at 6:04 PM
finance.yahoo.com logoSHAREHOLDER DEADLINE ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Keryx Biopharmaceuticals Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm (NASDAQ:KERX)
finance.yahoo.com - August 11 at 6:04 PM
finance.yahoo.com logoCohen Milstein Sellers & Toll PLLC Announces the Investigation of Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX)
finance.yahoo.com - August 11 at 6:04 PM
finance.yahoo.com logoIMPORTANT KERYX BIOPHARMACEUTICALS INC. SHAREHOLDER ALERT: Wolf Haldenstein Adler Freeman & Herz LLP Announces that a Class Action Lawsuit has been Commenced on Behalf of Shareholders of Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX)
finance.yahoo.com - August 11 at 6:04 PM
News IconBragar Eagel & Squire, P.C. (NASDAQ:KERX)
www.enhancedonlinenews.com - August 11 at 8:54 AM
capitalcube.com logoKeryx Biopharmaceuticals, Inc. :KERX-US: Earnings Analysis: Q2, 2016 By the Numbers : August 10, 2016 (NASDAQ:KERX)
www.capitalcube.com - August 10 at 6:06 PM
finance.yahoo.com logoBragar Eagel & Squire, P.C. Announces That a Class Action Lawsuit Has Been Filed against Keryx Biopharmaceuticals, Inc. (KERX) and Encourages Investors to Contact the Firm (NASDAQ:KERX)
finance.yahoo.com - August 10 at 6:06 PM
News IconScorching Biotech Stocks in Action- Keryx Biopharmaceuticals (NASDAQ:KERX), Ocular Therapeutix (NASDAQ:OCUL) - Seneca Globe (NASDAQ:KERX)
www.senecaglobe.com - August 10 at 8:47 AM
streetupdates.com logoAnalyst's Overview of Two Stocks: Horizon Pharma plc (NASDAQ:HZNP) , Keryx Biopharmaceuticals, Inc. (NASDAQ ... - Street Updates (NASDAQ:KERX)
www.streetupdates.com - August 10 at 8:47 AM
News IconConsiderable Healthcare Stocks- Skyline Medical (NASDAQ:SKLN), Keryx Biopharmaceuticals (NASDAQ:KERX) - Seneca Globe (NASDAQ:KERX)
www.senecaglobe.com - August 10 at 8:47 AM
fortune.com logoWhich way Keryx Biopharmaceuticals Inc. (NASDAQ:KERX) insiders are heading - Review Fortune (NASDAQ:KERX)
reviewfortune.com - August 10 at 8:47 AM
equities.com logoKeryx Biopharmaceuticals Inc. (KERX) Drops 6.24% on August 08 ... - Equities.com (NASDAQ:KERX)
www.equities.com - August 10 at 8:47 AM
finance.yahoo.com logoRyan & Maniskas, LLP Announces Class Action Lawsuit Against Keryx Biopharmaceuticals Inc. (NASDAQ:KERX)
finance.yahoo.com - August 10 at 8:47 AM

Social

Keryx Biopharmaceuticals (NASDAQ:KERX) Chart for Saturday, August, 27, 2016


Last Updated on 8/27/2016 by MarketBeat.com Staff